Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Genetic engineering and coagulation factors.

D N Fass, J J Toole

    Clinics in Haematology
    |June 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Recombinant DNA technology offers promising new treatments for coagulation disorders like hemophilia. Gene therapy and diagnostic testing are advancing rapidly, with therapeutic trials anticipated soon for patients with these genetic diseases.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Potency and mass of factor VIII in FVIII products.

    Haemophilia : the official journal of the World Federation of Hemophilia·2008
    Same author

    Atrial fibrillation and thrombosis: immunohistochemical differences between in situ and embolized thrombi.

    Journal of thrombosis and haemostasis : JTH·2004
    Same author

    Platelet glass bead retention predicts bleeding after cardiac surgery.

    Journal of cardiothoracic and vascular anesthesia·2001
    Same author

    Antineutrophil cytoplasmic antibodies reacting with the pro form of proteinase 3 and disease activity in patients with Wegener's granulomatosis and microscopic polyangiitis.

    Arthritis and rheumatism·2001
    Same author

    Plasma aprotinin concentrations during cardiac surgery: full- versus half-dose regimens.

    Anesthesia and analgesia·2000
    Same author

    Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial.

    JAMA·1999
    Same journal

    Myelodysplastic syndromes.

    Clinics in haematology·1986
    Same journal

    In vitro culture techniques defining biological abnormalities in the myelodysplastic syndromes and myeloproliferative disorders.

    Clinics in haematology·1986
    Same journal

    Myelodysplastic syndromes: natural history and features of prognostic importance.

    Clinics in haematology·1986
    Same journal

    Pathogenesis and clinical variations in the myelodysplastic syndromes.

    Clinics in haematology·1986
    Same journal

    The treatment of myelodysplastic syndromes.

    Clinics in haematology·1986
    Same journal

    Secondary myelodysplastic syndromes and leukaemias.

    Clinics in haematology·1986
    See all related articles

    Area of Science:

    • Biotechnology and Genetic Engineering
    • Hematology and Coagulation Disorders

    Background:

    • Advances in thrombolytic therapy highlight the potential of recombinant technology.
    • Coagulation disorders currently lack the therapeutic progress seen in related fields.
    • The development of recombinant human tissue plasminogen activator (t-PA) shows promise for applying new technologies to hemostatic abnormalities.

    Purpose of the Study:

    • To explore the potential application of recombinant DNA technology and gene therapy in treating coagulation defects.
    • To project the future use of genetic engineering for patients with hemostatic compromise.
    • To discuss the feasibility and ethical considerations of genetic engineering in treating human diseases, particularly hemophilias.

    Main Methods:

    • Reviewing progress in related fields like thrombolytic therapy.

    Related Experiment Videos

  • Projecting advancements in genetic engineering and gene therapy onto coagulation disorders.
  • Analyzing the feasibility of cloning and gene therapy in mammalian systems.

    • Main Results:

    • Recombinant DNA technology is poised to revolutionize the treatment of coagulation defects.
    • Diagnostic testing using cloned DNA is already in progress for hemophilias.
    • Gene therapy feasibility is demonstrated, with investigative use approvals anticipated.

    Conclusions:

    • The haemophilias are expected to be among the first genetic diseases treated with recombinant DNA technology.
    • The future of treating coagulation disorders with genetic engineering is rapidly approaching.
    • Ethical and regulatory frameworks are being developed to address the use of genetic engineering in medicine.